DARS2 overexpression is associated with PET/CT metabolic parameters and affects glycolytic activity in lung adenocarcinoma

Abstract

Background This study investigated the correlation between the expression of DARS2 and metabolic parameters of 18F-FDG PET/CT, and explored the potential mechanisms of DARS2 affecting the proliferation and glycolysis of lung adenocarcinoma (LUAD) cells. Methods This study used genomics and proteomics to analyze the difference in DARS2 expression between LUAD samples and control samples. An analysis of 62 patients with LUAD who underwent 18F-FDG PET/CT examinations before surgery was conducted retrospectively. The correlation between DARS2 expression and PET/CT metabolic parameters, including SUVmax, SUVmean, MTV, and TLG, was examined by Spearman correlation analysis. In addition, the molecular mechanism of interfering with DARS2 expression in inhibiting LUAD cell proliferation and glycolysis was analyzed through in vitro cell experiments. Results DARS2 expression was significantly higher in LUAD samples than in control samples (p < 0.001). DARS2 has high specificity (98.4%) and sensitivity (95.2%) in the diagnosis of LUAD. DARS2 expression was positively correlated with SUVmax, SUVmean, and TLG (p < 0.001). At the same time, the sensitivity and specificity of SUVmax in predicting DARS2 overexpression in LUAD were 88.9% and 65.9%, respectively. In vitro cell experiments have shown that interfering with DARS2 expression can inhibit the proliferation and migration of LUAD cells, promote cell apoptosis, and inhibit the glycolytic activity of tumor cells by inhibiting the expression of glycolytic related genes SLC2A1, GPI, ALDOA, and PGAM1. Conclusions Overexpression of DARS2 is associated with metabolic parameters on 18F-FDG PET/CT, which can improve LUAD diagnosis accuracy. DARS2 may be a useful biomarker to diagnose, prognosis, and target treatment of LUAD patients.

TRIP6 a potential diagnostic marker for colorectal cancer with glycolysis and immune infiltration association

“…Previous studies have reported that enhanced glycolytic activity in tumor cells correlates positively with 18 F-FDG uptake. Thus, by measuring the uptake values of 18 F-FDG (SUV), one could indirectly reflect the glycolytic activity and metabolic status of the tumor cells 44 – 47 . In our current study, analysis of the GSE110224 dataset revealed a positive correlation between TRIP6 expression and 18 F-FDG metabolic parameters (SUV), suggesting that an increase in TRIP6 expression could potentially lead to significant changes in SUV levels.…”

METTL3 as a novel diagnosis and treatment biomarker and its association with glycolysis, cuproptosis and ceRNA in oesophageal carcinoma

“…Subsequently, observation and image analysis were conducted using a fluorescence microscope. For a detailed experimental protocol, please refer to our previous research 40 …”

SPC25 as a novel therapeutic and prognostic biomarker and its association with glycolysis, ferroptosis and ceRNA in lung adenocarcinoma

“…Once their density reached 70-80%, the siRNA was transfected into cells using Lipofectamine 3000 transfection reagent (L3000015, Invitrogen). For a detailed experimental protocol, please refer to our previous studies [30].…”